-+ 0.00%
-+ 0.00%
-+ 0.00%

U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer

Barchart·06/03/2025 15:30:00
Listen to the news

ORION CORPORATION
PRESS RELEASE
3 JUNE 2025 at 23.30 EEST          

U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.